2006 Bethesda international consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications

Cytometry Part B - Clinical Cytometry

Volumn 72, Issue SUPPL. 1, 2007, Pages

  Davis, Bruce H ^a,n   Holden, J T ^b   Bene, M C ^c   Borowitz, M J ^d   Braylan, R C ^e   Cornfield, D ^f   Gorczyca, W ^g   Lee, R ^h   Maiese, R ⁱ   Orfao, A ^j   Wells, D ^k   Wood, B L ^l   Stetler Stevenson, M ^m  

^a Trillium Diagnostics   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f LEHIGH VALLEY HOSPITAL   (United States)

^g Genzyme Genetics   (United States)

^h Molecular Pathology Laboratory Network Inc   (United States)

ⁱ Ameripath Inc   (United States)

^j CSIC   (Spain)

^k HEMATOLOGICS INC   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ NONE   (United States)

more..

Author keywords

Leukemia diagnosis; Lymphoma diagnosis; Lymphoproliferative disorder; Multiple myeloma; Myelodysplasia

Indexed keywords

ANTIGEN EXPRESSION; CANCER DIAGNOSIS; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DIAGNOSTIC VALUE; FLOW CYTOMETRY; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL COOPERATION; MEDICAL SOCIETY; PRIORITY JOURNAL; PROGNOSIS;

FLOW CYTOMETRY; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; PARAPROTEINEMIAS;

EID: 36649021359     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20365     Document Type: Conference Paper

References (188)

1. Stelzer GT, Marti G, Hurley A, McCoy P Jr, Lovett EJ, Schwartz A. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 1997;30(5):214-230.
2. Stewart CC, Behm FG, Carey JL, Cornbleet J, Duque RE, Hudnall SD, Hurtubise PE, Loken M, Tubbs RR, Wormsley S. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations. Cytometry 1997;30(5):231-235.
3. Borowitz MJ, Bray R, Gascoyne R, Melnick S, Parker JW, Picker L, Stetler-Stevenson M. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry 1997;30(5):236-244.
4. Braylan RC, Atwater SK, Diamond L, Hassett JM, Johnson M, Kidd PG, Leith C, Nguyen D. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data reporting. Cytometry 1997;30(5):245-248.
5. Davis BH, Foucar K, Szczarkowski W, Ball E, Witzig T, Foon KA, Wells D, Kotylo P, Johnson R, Hanson C, and others. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. Cytometry 1997;30(5):249-263.
6. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry 2001;46(1):23-27.
7. Jaffe E, Harris N, Stein H, Vardiman J. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues Lyon: IARC Press; 2001.
8. Jennings C, Foon K. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy Blood 1997;90(8):2863-2892.
9. Arroyo J, Fernandez M, Hernandez J, Orfao A, San Miguel J, Canizo M. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J 2004;5(3):227-233.
10. Bargetzi MJ, Wortelboer M. Severe neutropenia in T-large granular lymphocyte leukemia corrected by intensive immunosuppression. Ann Hematol 1996;73(3):149-151.
11. Benesch M, Deeg HJ. Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. Hematology 2004;9(3):171-177.
12. Bible K, Ca AT. Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol 1996;93(2):406-408.
13. Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev 2006;20(5):245-266.
14. Cherian S, Moore J, Bantly A, Vergilio J, Klein P, Luger S, Bagg A. Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol 2005;79(3):243-245.
15. Cherian S, Moore J, Bantly A, Vergilio J, Klein P, Luger S, Bagg A. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 2005;64B(1):9-17.
16. Kussick S, Wood B. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 2003;127(9):1140-1147.
17. Kwong Y, La KFW. Association of pure red cell aplasia with T large granular lymphocyte leukaemia. J Clin Pathol 1998;51(9):672-675.
18. Maynadie M, Picard F. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002;100(7):2349-2356.
19. Pastor E, Sayas M. Severe neutropenia associated with large granular lymphocyte lymphocytosis: successful control with cyclosporin A. Blut 1989;59(6):501-502.
20. Sood R, Stewart CC. Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998;91(9):3372-3378.
21. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001;98(4):979-987.
22. Wells DA, Hall MC. Occult B cell malignancies can be detected by three-color flow cytometry in patients with cytopenias. Leukemia 1998;12(12):2015-2023.
23. Wells DA, Benesch M. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102(1):394-403.
24. Ahmad E, Garcia C, Davis B. Clinical utility of CD23 and FMC-7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification. Cytometry 2002;50:1-7.
25. Brown K. Nonmalignant disorders of lymphocytes. Clin Lab Sci 1997;10:329-335.
26. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87(12):4990-4997.
27. Cro L, Guffanti A, Colombi M, Cesana B, Grimoldi MG, Patriarca C, Goldaniga M, Neri A ID, Cortelezzi A, Maiolo AT, Baldini L. Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias. Leukemia 2003;17(1):125-132.
28. Dahmoush L, Hijazi Y, Barnes E, Stetler-Stevenson M, Abati A. Adult T-cell leukemia/lymphoma: a cytopathologic, immunocytochemical, and flow cytometric study. Cancer 2002;96(2):110-116.
29. DiGiuseppe J, Borowitz M. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998;25(1):6-10.
30. Frater J, McCarron K, Hammel J, Shapiro J, Miller M, Tubbs R, Pettay J, Hsi E. Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol 2001;116:655-664.
31. Geisler C, Larsen J, Hansen N, Hansen M, Christensen B, Lund B, Nielsen H, Plesner T, Thorling K, Andersen E. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991;78(7):1795-1802.
32. Gorczyca W, Weisberger J, Liu Z, Tsang P, Hossein M, Wu C, Dong H, Wong J, Tugulea S, Dee S, and others. An approach to diagnosis of T-cell lymphoproliferative disorders by flow cytometry. Cytometry 2002;50(3):177-190.
33. Hudnall S, Pael J, Schwab H, Martinez J. Comparative immunophenotypic features of EBV-positive and EBV-negative atypical lymphocytosis. Cytometry B Clin Cytom 2003;55B:22-28.
34. Jones D, Dang N, Duvic M, Washington L, Huh Y. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001;115(6):885-892.
35. Karandikar N, Hotchkiss E, Mckenna R, Kroft S. Transient stress lymphocytosis: an immunophenotypic characterization of the most common cause of newly identified adult lymphocytosis in a tertiary hospital. Am J Clin Pathol 2002;116(3):662-666.
36. Langerak A, van Den Beemd R, Wolvers-Tettero I, Boor P, van Lochem E, Hooijkaas H, van Dongen J. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood 2001;98(1):165-173.
37. Marti GE, Rawstron AC. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005;130(3):325-332.
38. Matutes E, Owusu-Ankomah K, Morilla R, Garcia M, Houlihan A, Que T, Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8(10):1640-1645.
39. Morice W, Katzmann J, Pittelkow M, el-Azhary R, Gibson L, Hanson C. A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sezary syndrome. Am J Clin Pathol 2006;125(3):364-374.
40. Nelson B, Variakojis D, Peterson L. Leukemic phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation. Mod Pathol 2002;15(11):1111-1120.
41. Rawstron A. Prevalence and characteristics of monoclonal B-cell lymphocytosis (MBL) in healthy individuals and the relationship with clinical disease. J Biol Regul Homeost Agents 2004;18(2):155-160.
42. Rawstron A, Green M, Kuzmicki A, Kennedy B, Fenton J, Evans P, O'Connor S, Richards S, Morgan G, Jack A, and others. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002;100(2):635-639.
43. Rose M, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist 2004;9(3):247-258.
44. Salcedo I, Campos-Caro A, Sampalo A, Reales E, Brieva J. Persistent polyclonal B lymphocytosis: an expansion of cells showing IgVH gene mutations and phenotypic features of normal lymphocytes from the CD27+ marginal zone B-cell compartment. Br J Haematol 2002;116(3):662-666.
45. Schlette E, Bueso-Ramos C, Giles F, Glassman A, Hayes K, Medeiros L. Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 2001;115(4):571-581.
46. Tworek J, Singleton T, Schnitzer B, Hsi E, Ross C. Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Am J Clin Pathol 1998;110(5):582-589.
47. Wang C, Amato D, Rabah R, Zheng J, Fernandes B. Differentiation of monoclonal B lymphocytosis of undetermined significance (MLUS) and chronic lymphocytic leukemia (CLL) with weak CD5 expression from CD5(-) CLL. Leuk Res 2002;26(12):1125-1129.
48. Xu Y, McKenna RW. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 2005;124(5):799-806.
49. Abruzzo LV, Jaffe ES, Cotelingam JD, Whang-Peng J, Del Duca V Jr, Medeiros LJ. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol 1992;16(3):236-245.
50. Berki T, David M, Bone B, Losonczy H, Vass J, Nemeth P. New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states. Pathol Oncol Res 2001;7(4):292-297.
51. Catovsky D, Bernasconi C, Verdonck PJ, Postma A, Hows J, van der Does-van den Berg A, Rees JK, Castelli G, Morra E, Galton DA. The association of eosinophilia with lymphoblastic leukaemia or lymphoma: a study of seven patients. Br J Haematol 1980;45(4):523-534.
52. Gallamini A, Carbone A, Lista P, Cavallero G, Reato G, Fruttero A, Novero D, Asnaghi G, di Celle PF, Foa R. Intestinal T-cell lymphoma with massive tissue and blood eosinophilia mediated by IL-5. Leuk Lymphoma 1995;17(1-2):155-161.
53. Lichtman M, Segel G. Uncommon phenotypes of acute myelogenous leukemia: basophilic, mast cell, eosinophilic, and myeloid dendritic cell subtypes: a review. Blood Cells Mol Dis 2005;35(3):370-383.
54. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. 'Idiopathic' eosinophilia with an Occult T-cell clone: Prevalence and clinical course. Leuk Res 2007;31(5):691-694.
55. Davis B. Improved Diagnostic Approaches to Infection/Sepsis Detection. Expert Rev Mol Diag 2005;5:193-207.
56. Davis B, Olsen S, Ahmad E, Bigelow N. Neutrophil CD64 is an improved indicator of infection or sepsis in emergency department patients. Arch Pathol Lab Med 2006;130(5):654-661.
57. Bene M, Bernier M, Casasnovas R, Castoldi G, Doekharan D, van der Holt B, Knapp W, Lemez P, Ludwig W, Matutes E, and others. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 2001;113(3):737-745.
58. Borowitz M, Hunger S, Carroll A, Shuster J, Pullen D, Steuber C, Cleary M. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood 1993;82(4):1086- 1091.
59. Borowitz M, Rubnitz J, Nash M, Pullen D, Camitta B. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. Leukemia 1998;12(11):1764-1770.
60. Brunning R. Classification of acute leukemias. Semin Diagn Pathol 2003;20(3):142-153.
61. Casasnovas R, Slimane F, Garand R, Faure G, Campos L, Deneys V, Bernier M, Falkenrodt A, Lecalvez G, Maynadie M, and others. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003;17(3):515-527.
62. Cohen P, Hoyer J, Kurtin P, Dewald G, Hanson C. Acute myeloid leukemia with minimal differentiation. A multiple parameter study. Am J Clin Pathol 1998;109(1):32-38.
63. D'Arena G, Cascavilla N, Nunziata G, Perla G, Matera R, Carella A. Usefulness of RA and RO isoforms of common leukocyte antigen (CD45) for early distinction between normal and abnormal promyelocytes. Leuk Lymphoma 2002;43(9):1823-1825.
64. De Zen L, Bicciato S, te Kronnie G, Basso G. Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia; an MLL/AF4 identification. Leukemia 2003;17(8):1557-1565.
65. De Zen L, Orfao A, Cazzaniga G, Masiero L, Cocito M, Spinelli M, Rivolta A, Biondi A, Zanesco L, Basso G. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia 2000;14(7):1225-1231.
66. Dorfman D, Longtine J, Fox E, Weinberg D, Pinkus G. T-cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings. Am J Clin Pathol 1997;107(2):168-176.
67. Feuillard J, Jacob M, Valensi F, Maynadie M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drenou B, Duchayne E, and others. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002;99(5):1556-1563.
68. Haferlach T, Kern W, Schnittger S, Schoch C. Modern diagnostics in acute leukemias. Crit Rev Oncol Hematol 2005;56(2):223-234.
69. Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002;16(7):1233-1258.
70. Hurwitz C, Raimondi S, Head D, Krance R, Mirro JJ, Kalwinsky D, Ayers G, Behm F. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992;80(12):3182-3188.
71. Jacob M, Chaperot L, Mossuz P, Feuillard J, Valensi F, Leroux D, Bene M, Bensa J, Briere F, Plumas J. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 2003;88(8):941-955.
72. Kaleem Z, Crawford E, Pathan M, Jasper L, Covinsky M, Johnson L, White G. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 2003;127(1):42-48.
73. Kaleem Z, White G. Diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-M0). Evaluation and a proposal. Am J Clin Pathol 2001;115(6):876-884.
74. Khalidi H, Brynes R, Medeiros L, Chang K, Slovak M, Snyder D, Arber D. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings. Mod Pathol 1998;11(12):1211-1221.
75. Kroft S. Role of flow cytometry in pediatric hematopathology. Am J Clin Pathol 2004;122(Suppl):S19-32.
76. Lai R, Hirsch-Ginsberg C, Bueso-Ramos C. Pathologic diagnosis of acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000;14(6):1209-1235.
77. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr 2005;217(3):126-134.
78. Legrand O, Perrot J, Simonin G, Baudard M, Cadiou M, Blanc C, Ramond S, Viguie F, Marie J, Zittoun R. Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Br J Haematol 1998;100(1):147-155.
79. Lichtman MA, Segel GB. Uncommon phenotypes of acute myelogenous leukemia: basophilic, mast cell, eosinophilic, and myeloid dendritic cell subtypes: a review. Blood Cells Mol Dis 2005;35(3):370-383.
80. Melnick S. Acute lymphoblastic leukemia. Clin Lab Med 1999;19(1):169-186.
81. Munoz L, Aventin A, Villamor N, Junca J, Acebedo G, Domingo A, Rozman M, Torres J, Tormo M, Nomdedeu J. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica 2003;88(6):637-645.
82. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006;108(3):1037-1044.
83. Orfao A, Chillon M, Bortoluci A, Lopez-Berges M, Garcia-Sanz R, Gonzalez M, Tabernero M, Garcia-Marcos M, Rasillo A, Hernandez-Rivas J, and others. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARA gene rearrangements. Haematologica 1999;84(5):405-412.
84. Orfao A, Ortuno F, de Santiago M, Lopez A, San Miguel J. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A 2004;58A(1):62-71.
85. Paietta E, Racevskis J, Neuberg D, Rowe J, Goldstone A, Wiernik P. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. Leukemia 1997;11(11):1887-1890.
86. Porwit-MacDonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, Walker H, Turker A, Goldstone A, Burnett A. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 1996;87(3):1162-1169.
87. Reichard K, Burks E, Foucar M, Wilson C, Viswanatha D, Hozier J, Larson R. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 2005;29(10):1274-1283.
88. Riley R, Massey D, Jackson-Cook C, Idowu M, Romagnoli G. Immunophenotypic analysis of acute lymphocytic leukemia. Hematol Oncol Clin North Am 2002;16(2):245-299.
89. Rizzatti E, Portieres F, Martins S, Rego E, Zago M, Falcao R. Microgranular and t(11;17)/PLZF-RARA variants of acute promyelocytic leukemia also present the flow cytometric pattern of CD13, CD34, and CD15 expression characteristic of PML-RARA gene rearrangement. Am J Hematol 2004;76(1):44-51.
90. Schwartz S, Rieder H, Schlager B, Burmeister T, Fischer L, Thiel E. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/ CD65s(+)/CD15(+) B-cell phenotype. Leukemia 2003;17(8):1589-1595.
91. Stasi R, Amadori S. AML-M0: a review of laboratory features and proposal of new diagnostic criteria. Blood Cells Mol Dis 1999;25(2):120-129.
92. Sulak L, Clare C, Morale B, Hansen K, Montiel M. Biphenotypic acute leukemia in adults. Am J Clin Pathol 1990;94(1):54-8.
93. te Kronnie G, Bicciato S, Basso G. Acute leukemia subclassification: a marker protein expression perspective. Hematology 2004;9(3):165-170.
94. Todd W. Acute myeloid leukemia and related conditions. Hematol Oncol Clin North Am 2002;16(2):301-319.
95. Weir E, Borowitz M. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol 2001;38(2):124-138.
96. Williams S, Wellhausen S, Barker R, Janckila A. Acute bilineage leukemia after chronic myelogenous leukemia. J Ky Med Assoc 1997;95(9):393-396.
97. Zeleznikova T, Babusikova O. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry. Neoplasma 2005;52(6):517-522.
98. Ceyhan B, Demiralp E, Celikel T. Analysis of pleural effusions using flow cytometry. Respiration 1996;63(1):17-24.
99. Czader M, Ali S. Flow cytometry as an adjunct to cytomorphologic analysis of serous effusions. Diagn Cytopathol 2003;29(2):74-78.
100. Stonesifer K, Xiang J, Wilkinson E, Benson N, Braylan R. Flow cytometric analysis and cytopathology of body cavity fluids. Acta Cytol 1987;31(2):125-130.
101. Finn W, Peterson L, James C, Goolsby C. Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. Am J Clin Pathol 1998;110(3):341-346.
102. Roma A, Garcia A, Avagnina A, Rescia C, Elsner B. Lymphoid and myeloid neoplasms involving cerebrospinal fluid: comparison of morphologic examination and immunophenotyping by flow cytometry. Diagn Cytopathol 2002;27(5):271-275.
103. Subira D, Gorgolas M, Castanon S, Serrano C, Roman A, Rivas F, Tomas J. Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med 2005;6(1):21-26.
104. Davis J, Viciana A, Ruiz P. Diagnosis of intraocular lymphoma by flow cytometry. Am J Ophthalmol 1997;124(3):362-372.
105. Ohta K. [T lymphocyte subsets in aqueous humor from patients with uveitis]. Nippon Ganka Gakkai Zasshi 1996;100(11):899-904.
106. Zaldivar R, Martin D, Holden J, Grossniklaus H. Primary intraocular lymphoma: clinical, cytologic, and flow cytometric analysis. Ophthalmology 2004;111(9):1762-1767.
107. Garcia C, Rooney M, Ahmad E, Davis BH. Diagnostic usefulness of CD23 and FMC-7 antigen expression in B cell lymphoma classification. Amer J Clin Pathol 2001;115:258-265.
108. Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzales M, Garcia-Sanz R, Lopez-Berges M, Moro M, Hernandez J, Escribano L and others. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152(6):1655-1665.
109. Kumar S, Kimlinger T, Lust J, Donovan K, Witzig T. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 2003;102(3):1075- 1077.
110. Kumar S, Rajkumar S, Kyle R, Lacy M, Dispenzieri A, Fonseca R, Lust J, Gertz M, Greipp P, Witzig T. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005;23(24):5668-5674.
111. Nowakowsi G, Witzig T, Dingli D, Tracz M, Gertz M, Lacy M, Lust J, Dispenzieri A, Greipp P, Kyle R, and others. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005;106(7):2276-2279.
112. Owen R, Rawstron A. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice. Br J Haematol 2005;128(5):732-733.
113. Perez-Andres M, Almeida J, Martin-Ayuso M, Moro M, Martin-Nunez G, Galende J, Borrego D, Rodriguez M, Ortega F, Hernandez J, and others. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005;19:449-455.
114. Sahara N, Takeshita A, Shigeno K. Clinicopathological and prognostic characteristics of CD56- negative multiple myeloma. British Journal of Hematology 2002;117:882-885.
115. Cannon C, Richardson L. Value of flow cytometry in the evaluation of head and neck fine-needle lymphoid aspirates: a 3-year retrospective review of a community-based practice. Otolaryngol Head Neck Surg 2001;124:544-548.
116. Chen L, Kuriakose P, Hawley R, Janakiraman N, Maeda K. Hematologic malignancies with primary retroperitoneal presentation: clinicopathologic study of 32 cases. Arch Pathol Lab Med 2005;129:655-660.
117. Chen Y, Savargaonkar P, Fuchs A, Wasserman P. Role of flow cytometry in the diagnosis of lymphadenopathy in children. Diagn Cytopathol 2002;26:5-9.
118. Gong J, Snyder M, Lagoo A, Vollmer R, Dash R, Madden J, Buckley P, Jones C. Diagnostic impact of core-needle biopsy on fine-needle aspiration of non-Hodgkin lymphoma. Diagn Cytopathol 2004;31:23-30.
119. Liu K, Stern R, Rogers R, Dodd L, Mann K. Diagnosis of hematopoietic processes by fine-needle aspiration in conjunction with flow cytometry: A review of 127 cases. Diagn Cytopathol 2001;24:1-10.
120. Mehra M, Tamhane A, Eloubeidi M. EUS-guided FNA combined with flow cytometry in the diagnoses of suspected or recurrent intrathoracic or retroperitoneal lymphoma. Gastrointest Endosc 2005;62:508-513.
121. Mourad W, Tulbah A, Shoukri M, Al Dayel F, Akhtar M, Ali M, Hainau B, Martin J. Primary diagnosis and REAL/WHO classification of non-Hodgkin's lymphoma by fine-needle aspiration: cytomorphologic and immunophenotypic approach. Diagn Cytopathol 2003;28:191-195.
122. Ravoet C, Demartin S, Gerard R, Dehon M, Peny M, Petit B, Delannoy A, Husson B. Contribution of flow cytometry to the diagnosis of malignant and non malignant conditions in lymph node biopsies. Leuk Lymphoma 2004;45:1587-1593.
123. Ribeiro A, Vazquez-Sequeiros E, Wiersema L, Wang K, Clain J, Wiersema M. EUS-guided fine-needle aspiration combined with flow cytometry and immunocytochemistry in the diagnosis of lymphoma. Gastrointest Endosc 2001;53:485-491.
124. Sigstad E, Dong H, Davidson B, Berner A, Tierens A, Risberg B. The role of flow cytometric immunophenotyping in improving the diagnostic accuracy in referred fine-needle aspiration specimens. Diagn Cytopathol 2004;31:159-163.
125. Young N, Al Saleem T, Ehya H, Smith M. Utilization of fine-needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma. Cancer 1998;84:252-261.
126. Zeppa P, Marino G, Troncone G, Fulciniti F, De Renzo A, Picardi M, Benincasa G, Rotoli B, Vetrani A, Palombini L. Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions. Cancer 2004;102:55-65.
127. Eloubeidi M, Varadarajulu S, Eltoum I, Jhala D, Chhieng D, Jhala N. Transgastric Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy and Flow Cytometry of Suspected Lymphoma of the Spleen. Endoscopy 2006;38(6):617-620.
128. Almasri N, Zaer F, Iturraspe J, Braylan R. Contribution of flow cytometry to the diagnosis of gastric lymphomas in endoscopic biopsy specimens. Mod Pathol 1997;10:650-656.
129. Wu HSM, Millenson MM, Nicolaou N, Van Deerlin VM, Addya K, Lessin S, al Saleem T. Contribution of flow cytometry in the diagnosis of cutaneous lymphoid lesions. J Invest Dermatol 2003;121:1522-1530.
130. Zaer F, Braylan R, Zander D, Iturraspe J, Almasri N. Multiparametric flow cytometry in the diagnosis and characterization of low-grade pulmonary mucosa-associated lymphoid tissue lymphomas. Mod Pathol 1998;11:525-532.
131. Fromm J, Kussick S, Wood B. Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. Amer J Clin Pathol 2006;126:764-780.
132. Duggan PR, Easton D, Luider J, Auer IA. Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry: correlation with morphology. Cancer 2000;88(4):894-899.
133. Hanson CA, Kurtin PJ, Katzmann JA, Hoyer JD, Li CY, Hodnefield JM, Meyers CH, Habermann TM, Witzig TE. Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood 1999;94(11):3889-3896.
134. van der Velden V, Hoogeveen P, Pieters R, van Dongen J. Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia. Br J Haematol 2006;133:382-388.
135. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer M, Catovsky D. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22(2):185-191.
136. Perz J, Topaly J, Fruehauf S, Hensel M, Ho A. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2002;43(1):149-151.
137. Baer M. Detection of minimal residual disease in acute myeloid leukemia. Curr Oncol Rep 2002;4(5):398-402.
138. Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald A. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 2003;17(1):138-148.
139. Brinkman K, van Dongen JJ. Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vbeta antibodies. Leukemia 1998;12(2):150-154.
140. Campana D. Minimal residual disease studies in acute leukemia. Am J Clin Pathol 2004;122(Suppl):S47-57.
141. Coustan-Smith E, Ribeiro R, Rubnitz J, Razzouk B, Pui C, Pounds S, Andreansky M, Behm F, Raimondi S, Shurtleff S, and others. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003;123(2):243-252.
142. Coustan-Smith E, Sancho J, Hancock M, Boyett J, Behm F, Raimondi S, Sandlund J, Rivera G, Rubnitz J, Ribeiro R, and others. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96(8):2691-2696.
143. Dworzak M, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, Fritsch G, Gadner H, Austrian Berlin-Frankfurt-Munster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99(6):1952-1958.
144. Dworzak M, Panzer-Grumayer E. Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. Leuk Lymphoma 2003;44(9):1445-1455.
145. Feller N, van der Pol M, van Stijn A, Weijers G, Westra A, Evertse B, Ossenkoppele G, Schuurhuis G. Minimal residual disease parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004;18(8):1380-1390.
146. Griesinger F, Piro-Noack M, Kaib N, Falk M, Renziehausen A, Troff C, Grove D, Schnittger S, Buchner T, Ritter J, and others. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br J Haematol 1999;105(1):241-255.
147. Kern W, Schoch C, Haferlach T, Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005;56(2):283-309.
148. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104(10):3078-3085.
149. Krampera M, Vitale A, Vincenzi C, Perbellini O, Guarini A, Annino L, Todeschini G, Camera A, Fabbiano F, Fioritoni G, and others. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol 2003;120(1):74-79.
150. Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A, Campo E, Bosch F, Montserrat E. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006;107:4563-4569.
151. Moreton P, Kennedy B, Lucas G, Leach M, Rassam S, Haynes A, Tighe J, Oscier D, Fegan C, Rawstron A, and others. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23(13):2971-2979.
152. Raanani P, Ben-Bassat I. Detection of minimal residual disease in acute myelogenous leukemia. Acta Haematol 2004;112(1-2):40-54.
153. Rawstron A, Kennedy B, Evans P, Davies F, Richards S, Haynes A, Russell N, Hale G, Morgan G, Jack A, and others. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001;98(1):29-35.
154. San Miguel J, Martinez A, Macedo A, Vidriales M, Lopez-Berges C, Gonzalez M, Caballero D, Garcia-Marcos M, Ramos F, Fernandez-Calvo J, and others. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90(6):2465-2470.
155. Sanchez J, Serrano J, Gomez P, Martinez F, Martin C, Madero L, Herrera C, Garcia J, Casano J, Torres A. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 2002;116(3):686-694.
156. Shulman H, Wells D, Gooley T, Myerson D, Bryant E, Loken M. The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry. Am J Clin Pathol 1999;112(4):513-523.
157. Sievers E, Lange B, Alonzo T, Gerbing R, Bernstein I, Smith F, Arceci R, Woods W, Loken M. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003;101(9):3398-3406.
158. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, Battaglia A, Catalano G, Del Moro B, Cudillo L, and others. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96(12):3948-3952.
159. Venditti A, Maurillo L, Buccisano F, Tamburini A, Del Poeta G, Del Principe M, Panetta P, Consalvo M, Mazzone C, Tendas A, and others. Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Leuk Lymphoma 2003;44(3):445-450.
160. Venditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Tamburini A, Del Principe M, Consalvo M, De Fabritiis P, Cudillo L, and others. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 2003;17(11):2178-2182.
161. Vidriales M, Orfao A, San-Miguel J. Immunologic monitoring in adults with acute lymphoblastic leukemia. Curr Oncol Rep 2003;5(5):413-418.
162. Vidriales M, Perez J, Lopez-Berges M, Gutierrez N, Ciudad J, Lucio P, Vazquez L, Garcia-Sanz R, del Canizo M, Fernandez-Calvo J, and others. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003;101(12):4695-4700.
163. Yin J, Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 2002;360(9327):160-162.
164. Lai R, Arber D. Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature. Am J Clin Pathol 1999;111(3):373-378.
165. Martinez A, Pittaluga S, Villamor N, Colomer D, Rozman M, Raffeld M, Montserrat E, Campo E, Jaffe E. Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis. Am J Surg Pathol 2004;28(7):849-858.
166. Mitterbauer G, Schwarzmeier J, Mitterbauer M, Jaeger U, Fritsch G, Schwarzinger I. Myelodysplastic syndrome/acute myeloid leukemia supervening previously untreated chronic B-lymphocytic leukemia: demonstration of the concomitant presence of two different malignant clones by immunologic and molecular analysis. Ann Hematol 1997;74:193-197.
167. Molica S. Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies. Leuk Lymphoma 2005;46:49-54.
168. Muta T, Okamura T, Nino Y. Acute myelogenous leukemia concurrent with untreated chronic lymphocytic leukemia. Int J Hematol 2002;75(2):187-190.
169. Saunthararajah Y, Molldrem JL. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 2001;112(1):195-200.
170. Sokol L, Agosti S. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Am J Hematol 2004;75(2):107-109.
171. Perez-Persona E, Vidriales B, Mmateo G, Mateos M, Garcia A, Galende J, Nuñez G, Alonso J, de las Heras N, Hernández J, and others. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;doi:10.1182.
172. Alimena G, Breccia M, Latagliata R, Carmosino I, Russo E, Biondo F, Diverio D, Mancini M, Nanni M, Mandelli F. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 2006;107(5):1008-1013.
173. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno A, Capelli G, Tamburini A, Suppo G, Battaglia A, Del Principe M, and others. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98(9):2633-2639.
174. Birhiray R, Shaw G, Guldan S, Rudolf D, Delmastro D, Santabarbara P, Brettman L. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia 2002;16(5):861-864.
175. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348(18):1764-1775.
176. Durig J, Naschar M, Schmucker U, Renzing-Kohler K, Holter T, Huttmann A, Duhrsen U. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002;16(1):30-35.
177. Schroers R, Griesinger F, Trumper L, Haase D, Kulle B, Klein-Hitpass L, Sellmann L, Duhrsen U, Durig J. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19(5):750-758.
178. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, and others. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351(9):893-901.
179. Richardson SJ, Matthews C, Catherwood MA, Alexander HD, Carey BS, Farrugia J, Gardiner A, Mould S, Oscier D, Copplestone JA, and others. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107(9):3584-3592.
180. Borowitz M, Shuster J, Carroll A, Nash M, Look A, Camitta B, Mahoney D, Lauer S, Pullen D. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood 1997;89(11):3960-3966.
181. Donskoy E, Tausche F, Altman A, Quinn J, Goldschneider I. Association of immunophenotype with cerebrospinal fluid involvement in childhood B-lineage acute lymphoblastic leukemia. Am J Clin Pathol 1997;107(5):608-616.
182. Solary E, Casasnovas R, Campos L, Bene M, Faure G, Maingon P, Falkenrodt A, Lenormand B, Genetet N. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 1992;6(5):393-399.
183. Daniels J, Davis B, Houde-McGrail L, Byrd J. Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biological marker? Br J Haematol 1999;107(2):381-383.
184. Schabath R, Ratei R, Ludwig W. The prognostic significance of antigen expression in leukaemia. Best Pract Res Clin Haematol 2003;16(4):613-628.
185. Junghanss C, Waak M, Knopp A, Kleine H, Kundt G, Leithauser M, Hilgendorf I, Wolff D, Casper J, Freund M. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression. Neoplasma 2005;52(5):402-410.
186. Ito S, Ishida Y, Oyake T, Satoh M, Aoki Y, Kowata S, Uchiyama T, Enomoto S, Sugawara T, Numaoka H, and others. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma 2004;45(9):1783-1789.
187. Pope B, Brown R, Gibson J, Joshua D. The bone marrow plasma cell labeling index by flow cytometry. Cytometry 1999;38:286-292.
188. Trendle M, Leong T, Kyle R, Katzmann J, Oken M, Kay N, Van Ness B, Greipp P. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486. Am J Hematol 1999;61:232-237.